Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722463 | 0.85 | KMT2A (0.37) | KDM5AKDM4CKDM5BKDM4EALDH1A1 | |
| SCHEMBL21704264 | 0.84 | KCNJ1 (0.34) | KDM4EMTNR1AMTNR1BTUBB4ATUBB | |
| SCHEMBL30741071 | 0.82 | LCK (0.37) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31403654 | 0.76 | PSMD14 (0.45) | KDM5AKDM4CKDM5BKDM4EALDH1A1 | |
| SCHEMBL30971248 | 0.75 | KDM4E (0.38) | KDM5AKDM4CKDM5BNR4A2KDM4E | |
| SCHEMBL30971239 | 0.74 | GSK3B (0.40) | PTGER4KDM5AKDM4CKDM5BNR4A2 | |
| SCHEMBL2298868 | 0.73 | MAP3K5 (0.50) | PTGER4NR4A2KDM4EMTNR1AMTNR1B | |
| SCHEMBL30968526 | 0.72 | NOTUM (0.41) | PTGER4NR4A2KDM4EALDH1A1HPGD | |
| SCHEMBL21685893 | 0.72 | NOTUM (0.41) | PTGER4NR4A2KDM4EALDH1A1HPGD | |
| SCHEMBL21704217 | 0.72 | MAPT (0.34) | KDM4EALDH1A1SMN1; SMN2HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | VALO HEALTH, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3833441-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112823037-A | Inhibition of deubiquitinase USP25 and USP28 | 瓦洛早期发现股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033709-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033709-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PTGER4 3807/4885KDM5A 202/4885KDM4C 411/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | PTGER4 3807/4885KDM5A 202/4885KDM4C 411/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PTGER4 3807/4885KDM5A 202/4885KDM4C 411/4885 |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | USP28, USP25, USP30 | PTGER4 4388/4885KDM5A 433/4885KDM4C 1828/4885 |
| US-12252490-B2 | Inhibiting deubiquitinase USP25 and USP28 | USP28, USP25, USP30 | PTGER4 4388/4885KDM5A 433/4885KDM4C 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.